Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
(2) The human homolog of int-2, located on chromosome 11q13, is frequently amplified in human primary tumors and is comprised in an amplification unit encompassing the hst gene, which is often coamplified; the amplification at the 11q13 locus in breast carcinomas correlates with a poor outcome of the disease.
|
2677918 |
1989 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, in this study, locus 11q13 and FGF3 gene (11q13) function were investigated in a radiation and estrogen breast cancer model induced by high-LET (α-particle) radiation and estrogen exposure.
|
25333703 |
2014 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of the int-2/fgf-3 gene in aggressive human breast carcinomas.
|
1362493 |
1992 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Infrequent (< or =12%) or absent LOH was detected at the remaining loci, including several loci commonly mutated in breast cancer (i.e., INT2, PYGM, and NM23).
|
10619258 |
1999 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic alterations have been described in breast carcinomas under the headings of loss of heterozygosity (1p, 3p, 7q, 11p, 17p, 17 and 18q), mutations (p53, c-H-ras-1), and/or gene amplifications (c-myc, int-2/FGF3, and c-erbB-2/neu).
|
7671254 |
1995 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that, compared to amplification of HER2/NEU, MYC, or INT2 oncogene loci, p53 gene mutations and deletions are the most frequently observed genetic change in breast cancer related to a single gene.
|
1961733 |
1991 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
|
9380415 |
1997 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
|
1975511 |
1990 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features.
|
7914106 |
1994 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A rapid, non-radioactive approach based on qdPCR and fluorescent DNA technique was applied for determination of int-2 and c-erbB2 gene amplification and correlated with other prognostic factors in 70 breast cancer samples.
|
9329619 |
1997 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The CCND1-FGF19-FGF4-FGF3 gene cluster in human chromosome 11q13 is amplified in breast cancer, squamous cell carcinoma of head and neck, and bladder tumors, and is also translocated in parathyroid tumors and B-cell lymphoma.
|
12429977 |
2002 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
INT2 and HST RNA could be evidenced by RNA/RNA in situ hybridization in breast carcinomas.
|
2474139 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some of these mutations involve amplification of protooncogenes (c-myc, c-erbB-2, and int-2) that have been shown to contribute to experimentally induced breast cancer in mouse model systems.
|
2667653 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In an attempt to probe the significance of HST and INT-2 gene amplification in human breast carcinomas, we have surveyed the amplification status of five molecular markers located on the long arm of chromosome 11 (BCL-1, HST, INT-2 & SEA on 11q13, and ETS-1 on 11q23) in a population of 297 mammary tumors.
|
2181375 |
1990 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification and expression of these genes is particularly interesting in the context of oncovirus involvement, because INT2 is a homolog of mouse int2 which causes mammary carcinoma in mice when activated by integration of retrovirus mouse mammary tumor virus.
|
10786811 |
2000 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
|
9421359 |
1997 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.
|
23658459 |
2013 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The glutathione S-transferase gene (GST pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer.
|
1826346 |
1991 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have compared the cytosolic cath-D level and the amplification of three oncogenes: c-myc, neu-erb-B-2 and int-2 in 140 primary breast carcinomas and 64 axillary lymph nodes collected in 1987 and 1988 at the Cancer Center of Montpellier (Centre Paul Lamarque).
|
2141510 |
1990 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
|
7892157 |
1994 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To attain this goal, amplification of different oncogenes (HER-2/neu, c-MYC and INT-2) was studied in primary tumors of a series of 259 patients with breast cancer (median follow-up of 72 mo).
|
7607564 |
1995 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrated that the peptide FP16, acting as an FGF3 antagonist, is a promising therapeutic agent for the treatment of breast cancer.
|
26323695 |
2015 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first report of an association between amplification of the int-2 oncogene in breast tumours and a significantly increased risk of death from breast cancer, and suggests that int-2 may be useful for identifying breast-cancer patients having a poor prognosis.
|
8449602 |
1993 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Int-2 was amplified in 22% (96/440) of the primary breast carcinomas.
|
11445874 |
2001 |